Notably, the NeoSphere trial randomized 417 patients with HER2-positive breast cancer to four treatment arms, docetaxel plus trastuzumab, docetaxel plus trastuzumab and pertuzumab (THP), trastuzumab plus pertuzumab (HP), and docetaxel plus pertuzumab. Here, ERBB2 is linked to breast carcinoma.